文献速递肝病

致病性Ifit1+中性粒细胞由IRF7驱动促进肝损伤并成为急性肝衰竭治疗靶点

Pathogenic Ifit1 + neutrophils driven by IRF7 promote liver injury and represent a therapeutic target in acute liver failure.
PubMed 文献 · Hepatology · 2026-03-30

该研究通过小鼠ALF肝组织单细胞RNA测序发现Ifit1+中性粒细胞亚群扩增且跨病因保守,该亚群通过分泌FGL2加重炎症和肝细胞凋亡;IRF7是其上游转录调控因子,中性粒细胞特异性Irf7缺失或靶向抑制可减轻肝损伤、改善生存,ALF患者中该亚群亦扩增且与疾病严重程度相关。

要点

  • Ifit1+中性粒细胞亚群在多种病因ALF中扩增,通过分泌FGL2加重肝损伤。
  • IRF7是Ifit1+中性粒细胞分化的上游转录调控因子。
  • 靶向抑制IRF7可减轻小鼠肝损伤并改善生存,患者中该亚群与病情严重程度相关。

核心结论

  • IRF7-Ifit1+中性粒细胞-FGL2轴驱动急性肝衰竭发病,靶向抑制该轴是可行治疗策略。

研究设计与样本

  • 基于小鼠急性肝衰竭肝组织单细胞RNA测序鉴定中性粒细胞亚群,并在ALF患者中验证其翻译相关性。

主要发现

  • 小鼠ALF肝组织中Ifit1+中性粒细胞亚群扩增,且在不同病因间保守。
  • 该亚群通过放大炎症反应和诱导肝细胞凋亡加重肝损伤,FGL2为主要效应分子。
  • 中性粒细胞特异性Irf7缺失减少Ifit1+中性粒细胞扩增、降低FGL2产生、减轻肝损伤并改善生存。
  • 肝中性粒细胞靶向脂质纳米颗粒递送IRF7小分子抑制剂HS38选择性抑制肝脏中性粒细胞Irf7,减轻肝损伤。
  • ALF患者中Ifit1+中性粒细胞显著扩增,其丰度与疾病严重程度相关。

临床怎么用

  • IRF7-Ifit1+中性粒细胞-FGL2轴可作为急性肝衰竭的潜在治疗靶点,肝中性粒细胞靶向递送IRF7抑制剂策略值得进一步转化研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Acute liver failure (ALF) is a life-threatening disease with a high mortality rate and limited treatment options. Neutrophils rapidly infiltrate the injured liver, yet their functional heterogeneity and regulatory mechanisms remain poorly understood. We aimed to identify pathogenic neutrophil subsets in ALF and identify potential therapeutic targets. APPROACH AND RESULTS: Single-cell RNA sequencing of liver tissues from murine ALF revealed the expansion of Ifit1 + neutrophil subset, which was conserved across diverse etiologies. This subset exacerbates liver injury by amplifying inflammatory responses and inducing hepatocyte apoptosis. FGL2 was identified as the principal effector secreted by this subset. Mechanistically, IRF7 acted as an upstream transcriptional regulator of Ifit1 + neutrophil differentiation. Neutrophil-specific Irf7 deficiency reduced Ifit1 + neutrophil expansion, diminished FGL2 production, mitigated liver injury, and improved survival. Liver neutrophil-targeted lipid nanoparticles delivering the IRF7 small-molecule inhibitor HS38 selectively inhibited hepatic neutrophil Irf7, mitigating liver damage. Importantly, the translational relevance of this pathway is underscored by the significant expansion of Ifit1 + neutrophils in ALF patients, where their abundance correlated with disease severity. CONCLUSIONS: These findings delineate an IRF7-Ifit1 + neutrophil-FGL2 axis driving ALF pathogenesis and establish its targeted inhibition as a viable therapeutic strategy.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Lu Y, Zhang Y, Sun L, et al. Pathogenic Ifit1 + neutrophils driven by IRF7 promote liver injury and represent a therapeutic target in acute liver failure. Hepatology. 2026. PMID: 41911548. doi:10.1097/HEP.0000000000001738

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。